Gout - Drug Pipeline Landscape, 2023

Gout - Drug Pipeline Landscape, 2023

Gout is a form of inflammatory arthritis marked by recurring flare-ups of red, painful, hot, and swollen joints brought on by the crystallization of monosodium urate monohydrate.

The underlying cause of gout is related to the high levels of uric acid crystals. This might be due to diet, genetic predisposition, or underexcretion of urate.

Symptoms of gout are sudden onset of joint swelling, joint pain, heat in the affected area, and joint redness.

Gout is diagnosed by the identification of monosodium urate crystals in synovial fluid of the affected joint by performing the following tests Joint fluid test, X-ray imaging, Ultrasound, and Dual-energy computerized tomography.

The initial treatment of gout is to reduce the symptoms of acute attacks. Tentative support is provided by applying ice several times a day. Treatment for acute treatment includes NSAIDS, colchicine, and glucocorticoids. While for prevention, there are allopurinol, febuxostat, and probenecid.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve Gout treatment such as FYU-981, SEL-212A SHR4640 and others. Key players involved in the development of therapies to treat Gout are GeneScience Pharmaceuticals Co Ltd, Jiangsu HengRui, Medicine Co Ltd, LG Chem, Rigel Pharmaceuticals Inc, Shanton Pharma Co Ltd, and others. Three drugs are under late-stage Phase III clinical trials and thirteen drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development. In Dec 2022, LG Chem agreed with Innovent Biologics a representative biopharmaceutical company in China, to further enhance the business value of the global novel gout treatment project.

Report Highlights

Global Insight Service's, Gout - Drug Pipeline Landscape, 2023 report provides an overview of the Gout pipeline drugs. This report covers detailed insights on Gout drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Gout pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.